Benjamin (Beni) Rovinski has 27 years of investment, operational, managerial and research experience in the healthcare sector. He joined Lumira Capital in 2001, where he is a Managing Director, with an investment focus on mid-to late-stage private and public life sciences companies. Prior to joining Lumira Ventures, Beni held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur where he was a senior scientist and director of molecular virology. He led global R&D programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical-stage. Beni received a PhD in biochemistry from McGill University in Montréal and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. He obtained his undergraduate degree from Rice University in Houston. Beni's current and past board roles and investment responsibilities include several private and public companies, including Aurinia Pharmaceuticals (AUPH); KAI Pharmaceuticals [acquired by Amgen]; Morphotek [acquired by Eisai]; Cervelo Pharmaceuticals; Health Hero Network [acquired by Bosch]; Avalon Pharmaceuticals [Nasdaq: AVRX; acquired by Clinical Data, Inc.]; Inovise Medical, Inc.; Protana; Signature Biosciences; and SGX Pharmaceuticals [Nasdaq: SGXP; acquired by Eli Lilly]. He also serves on the Board of Directors of Life Sciences Ontario and volunteers for various personal career mentoring programs targeting young adult entrepreneurs. Beni is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 29 issued patents. Benjamin (Beni) Rovinski has 27 years of investment, operational, managerial and research experience in the healthcare sector. He joined Lumira Capital in 2001, where he is a Managing Director, with an investment focus on mid-to late-stage private and public life sciences companies. Prior to joining Lumira Ventures, Beni held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur where he was a senior scientist and director of molecular virology. He led global R&D programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical-stage. Beni received a PhD in biochemistry from McGill University in Montréal and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. He obtained his undergraduate degree from Rice University in Houston. Beni's current and past board roles and investment responsibilities include several private and public companies, including Aurinia Pharmaceuticals (AUPH); KAI Pharmaceuticals [acquired by Amgen]; Morphotek [acquired by Eisai]; Cervelo Pharmaceuticals; Health Hero Network [acquired by Bosch]; Avalon Pharmaceuticals [Nasdaq: AVRX; acquired by Clinical Data, Inc.]; Inovise Medical, Inc.; Protana; Signature Biosciences; and SGX Pharmaceuticals [Nasdaq: SGXP; acquired by Eli Lilly]. He also serves on the Board of Directors of Life Sciences Ontario and volunteers for various personal career mentoring programs targeting young adult entrepreneurs. Beni is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 29 issued patents.